Computer Model Challenges Breast Cancer Treatment Strategy

References

• Fisher B. The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res 1992; 52: 2371–2383
   PubMed Web of Science ®Google Scholar
• Skipper H, Schabel F, Jr. Quantitative and cytokinetic studies in experimental tumor systems. Cancer Medicine, JF Holland, E Frei, III. Lea & Febiger, Philadelphia 1982; 663–685
   Google Scholar
• Laird A. Dynamics of growth in tumors and in normal organisms. Natl Cancer Inst Monogr 1969; 30: 15–27
   PubMedGoogle Scholar
• Coldman AJ, Goldie JH. Role of mathematical modeling in protocol formulation in cancer chemotherapy. Cancer Treat Rep 1985; 69: 1041
   PubMedGoogle Scholar
• Retsky M, Wardwell R, Speer JA. Computer simulation of breast cancer growth and treatment. American Association for Medical Systems and Informatics Proceedings. 1984, 453–457
   Google Scholar
• Speer J, Petrosky V, Retsky M. A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res 1984; 44: 4124–4130
   PubMed Web of Science ®Google Scholar
• Retsky M, Wardwell R, Swartzendruber D. Prospective computerized simulation of breast cancer: A comparison of computer predictions with nine sets of biological and clinical data. Cancer Res 1987; 47: 4982–4987
   PubMed Web of Science ®Google Scholar
• Retsky M, Swartzendruber D, Wardwell R. Is Gompertz-ian kinetics a valid description of individual tumor growth. Med Hypoth 1990; 33: 95–106
   PubMed Web of Science ®Google Scholar
• Retsky M, Swartzendruber D, Wardwell R. Correspondence re: Larry Norton. A Gompertzian model of human breast cancer growth. Cancer Res 1988; 49: 6443–6444, 1989 48:7067–7071
   Google Scholar
• Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988; 48: 7067–7071
   PubMed Web of Science ®Google Scholar
• Hawking SW. A Brief History of Time from the Big Bang to Black Holes. Bantam, New York 1990; 7
   Google Scholar
• Shackney SE, McCormack GW, Cuchural GJ, Jr. Growth rate patterns of solid tumors and their relation to responsiveness to therapy—An analytic review. Ann Intern Med 1978; 89: 107–121
   PubMed Web of Science ®Google Scholar
• Arnerlov C, Emdin SO, Lundgren B. Breast carcinoma growth rate described by mammographic doubling time and S-phase fraction. Correlations to clinical and histopathologic factors in screened population. Cancer 1992; 70: 1928–1934
   PubMed Web of Science ®Google Scholar
• Steel GG. Cytokinetics of neoplasia. Cancer Medicine, JF Holland, E Frei, III. Lea & Febiger, Philadelphia 1982; 177–189
   Google Scholar
• Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
   PubMedGoogle Scholar
• Retsky M, Swartzendruber D, Wardwell R. Chemosensitivity correlation between a breast cancer computer model and clonogenic assay. Proc. Annual Meeting of the American Association for Cancer Research, Baltimore. Waverly Press, New Orleans 1988; 29: 477
   Google Scholar
• Jones SE, Dean JC, Young LA. The human tumor clonogenic assay in human breast cancer. J Clin Oncol 1985; 3: 92
   PubMed Web of Science ®Google Scholar
• Cornelisse CJ, Van de Velde C JH, Caspers R JC. DNA ploidy and survival in breast cancer patients. Cytometry 1987; 8: 225–234
   PubMedGoogle Scholar
• Retsky MW, Bame PD, Wardwell RH. Predicting the results of new therapies with an accurate breast cancer computer model. Proc. Annual Meeting of the American Association for Cancer Research, Baltimore. Waverly Press, New Orleans May, 1988; 29: 335
   Google Scholar
• Clark GM, Dressler LG, Owens MA. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989; 320: 627–633
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Fisher ER. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience. Natl Cancer Inst Monogr 1986; 1: 35–43
   Google Scholar
• Hellman S, DeVita VT, Jr. Principles of cancer biology: Kinetics of cellular proliferation. Cancer: Principles and Practices of Oncology, VT DeVita, Jr, S Hellman, S Rosenberg. JP Lippincott, Philadelphia 1982; 53
   Google Scholar
• Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res 1991; 551: 2–4
   Google Scholar
• DeVita V. The relationship between tumor mass and resistance to chemotherapy. Cancer 1983; 51: 1209–1220
   PubMed Web of Science ®Google Scholar
• Cooper MR, Cooper MR. Principles of medical oncology. The American Cancer Society Textbook of Clinical Oncology, AI Holleb, DJ Fink, GP Murphy. American Cancer Society, Atlanta 1991; 50
   Google Scholar
• Weiss RB, DeVita VT, Jr. Multimodal primary cancer treatment (adjuvant chemotherapy); current results and future prospects. Ann Intern Med 1979; 91: 251–260
   PubMed Web of Science ®Google Scholar
• Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971; 28: 1479–1499
   PubMed Web of Science ®Google Scholar
• Steel GG. Cell population kinetics in relation to the growth and treatment of cancer. Growth Kinetics of Tumours. Clarendon Press, Oxford 1977
   Google Scholar
• Meltzer A. Dormancy and breast cancer. J Surg Oncol 1990; 43: 181–188
   PubMed Web of Science ®Google Scholar
• Stewart T HM, Hollinshead AC, Raman S. Tumour dormancy: Initiation, maintenance and termination in animals and humans. Can Soc Cardiovasc Thorac Surg 1991; 34: 321–325
   Google Scholar
• Lampl M, Veldhuis JD, Johnson ML. Saltation and stasis: A model of human growth. Science 1992; 258: 801–803
   PubMed Web of Science ®Google Scholar
• Curtsinger JW, Fukui HH, Townsend ER. Demographys of genotypes: Failure of the limited life-span paradigm in Drosophila melanogaster. Science 1992; 258: 461–463
   PubMed Web of Science ®Google Scholar
• Uhr JW. Cancer dormancy: Studies of the murine BCL1 lymphoma. Cancer Res 1991; 51: 5045s–5053s, (Suppl)
   PubMed Web of Science ®Google Scholar
• Cellular Immune Mechanisms and Tumor Dormancy, T HM Stewart, EF Wheelock. CRC Press, Boca Raton, FL 1992
   Google Scholar
• Penn I. The effect of renal transplantation in patients with a history of curative therapy. Cellular Immune Mechanisms and Tumor Dormancy, THM Stewart, EF Wheelock. CRC Press, Boca Raton, FL 1992; 239–260
   Google Scholar
• Jasmin C. Tumor stem cells and their ecosystem: Therapeutic implications of a new concept. Local Immunity in Cancer. Regensberg & Biermann, MünsterGermany 1986
   Google Scholar
• Thomlinson RH. Measurement and management of carcinoma of the breast. Clin Radiol 1982; 33: 481–493
   PubMed Web of Science ®Google Scholar
• Alexander P. 2nd Gordon Hamilton Fairley Lecture. Need for new approaches to the treatment of patients in clinical remission, with special reference to acute myeloid leukemia. Br J Cancer 1982; 46: 151
   PubMed Web of Science ®Google Scholar
• Henderson IC. Biologic variations of tumors. Cancer 1992; 69: 1888–1895
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber RD, Castiglione M. Adjuvant therapy of breast cancer. Eur J Cancer 1991; 27: 389–399
   PubMed Web of Science ®Google Scholar
• Demicheli R, Moliterni M, Zambetti G. Analysis of breast cancer local recurrences supports the concept of tumor dormancy. Proc Am Soc Clin Oncol 1992; 11: 100
   Google Scholar
• Salmon SE. Future directions. Semin Oncol 1990; 17(4, Suppl 7)50–52
   PubMed Web of Science ®Google Scholar
• Mihich E. Meeting report—First Annual Pezcoller Symposium: Drug resistance—mechanisms and reversal. Cancer Res 1989; 49: 7168–7171
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 71–85
   PubMed Web of Science ®Google Scholar
• Davis PL, Shumway MH. Thio-tepa in treatment of metastatic cerebral malignancy. JAMA 1961; 175: 714–715
   PubMed Web of Science ®Google Scholar
• Bame P, Wardwell R, Swartzendruber D. International Breast Cancer Study Group VI: Prospective computer model predictions. 7th International Conf on the Adjuvant Therapy of Cancer, Tucson, AZ, 1993
   Google Scholar
• Fisher B, Brown A, Dimitrov N. Two months of doxorubicincyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonrespondent tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483–1496
   PubMed Web of Science ®Google Scholar